Skip to content

CURAPHARMA

Active Private limited companyfounded 2005active for 20 yearsWatertorenlaan 1, 1930 ZaventemKBO/BCE: BE 0878.122.786 subsidiary of

Lifetime

20 annual accounts with figures on one time axis
peak of €257,171 in 2011
€17,427▼ 25.3%
lowest -€50,231 in 2013
€7,040▼ 28.1%
peak of €134,902 in 2025
€134,902▲ 5.5%
€217,369▼ 16.0%
peak of 2.8 FTE in 2012
-not published
Board3 names since 2005
1 director
Owners
100%
Documentsfilings and deeds
28-05-202664 days before the deadline
2025abbreviated format
Gross margin from €23,315 to €17,427Result from €9,787 to €7,040Debts from €258,828 to €217,369Cash from €98,567 to €60,745

Key points

from the 2025 annual accounts

Equity

€134,902 ▲ 5.5%

CURAPHARMA has made a profit without a break since 2014.

Turnover

≈ €180,000 estimated

The abbreviated format states no turnover.

Filings

20 annual accounts since 2006
AprilJune31 JulyOctober2010201520202025

The 2019 accounts came 7 days late. The other nine of the last ten were filed on time.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 17,047 companies had the same profile as CURAPHARMA has now. Each dot stands for 43 companies, two years later.

94.3%
were still trading
5.0%
stopped another way
0.5%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a profit under 5% of the balance sheet

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 17,047 companies, not a prediction for CURAPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, , since 15-12-2005
  • 100%equity €377,413 (2026) · annual accounts 31-03-2025 of
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0878122786
reappointed as director acts as permanent representative · “De vennootschap heeft tot voorwerp:; De uitbating van één of meerdere apotheken overeenkomstig de…” (deed in Dutch) · General meeting of 29-11-2022 · Gazette deed
Company renamed from APOTHEEK DESCHEEMAEKER to CURAPHARMA Capital of €18,600, 1,860 shares · General meeting of 03-01-2013 · Gazette deed
New manager appointed, resigned · acts as permanent representative · General meeting of 02-01-2013 · Gazette deed
All 31 events

Comparable companies

same main activity, similar in size and age
Company
CURAPHARMA Zaventem €352,271 €17,427 38.3% -
APOTHEEK VANSCHOENWINKEL Leuven €366,242 €19,324 29.5% -
ST-MARTINUS Mol €301,577 €17,572 95.9% -
APOTHEEK FORUM Tongeren-Borgloon €465,640 €17,024 5.1% -
CP PHARMA Fléron €375,380 €26,030 93.7% -
APOTHEEK VANDEWALLE Ghent €488,284 €18,595 68.9% 0
APOTHEEK SCHOENAERS Wellen €345,167 €12,950 7.5% 0

These companies have the same main activity as CURAPHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €302,000 and €488,000, founded between 1995 and 2005.

Official details

Source: KBO
Status
Active since 22-12-2005Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730and 2 others
Joint committee
313Pharmacies and pricing offices · annual accounts 2022
Establishment unit
2.151.028.4481930 Zaventem, since 13-01-2006
Financial year end
31 December
Peppol
Reachable since 08-05-2025
Company details

Annual accounts 2025

€352,271▼ 8.9%
Filing
Filed on 28-05-2026, 64 days before the end of the filing period
Financials

Companies linked to CURAPHARMA

Parent and group

Insights on CURAPHARMA

CURAPHARMA files the abbreviated format. That format states no turnover. The gross margin fell from €149,313 in 2006 to €17,427 in 2025.

holds all the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about CURAPHARMA

What is the company number of CURAPHARMA?
The company number of CURAPHARMA is 0878.122.786. The VAT number is the same number with BE in front: BE 0878.122.786.
Where is CURAPHARMA based?
The registered office is at Watertorenlaan 1, 1930 Zaventem.Company details
What does CURAPHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of CURAPHARMA?
CURAPHARMA is a private limited company (BV).
When was CURAPHARMA founded?
CURAPHARMA was founded on 22-12-2005.
Is CURAPHARMA still active?
Yes, CURAPHARMA is an active enterprise in the KBO register.
How many employees does CURAPHARMA have?
CURAPHARMA had an average of 0.3 full-time equivalents in financial year 2018, according to the filed annual accounts.Financials
Which joint committee does CURAPHARMA fall under?
In its 2022 annual accounts, CURAPHARMA states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of CURAPHARMA?
The turnover in financial year 2025 is ≈ €180,000. This figure is estimated from the gross margin of €17,427 and 168 comparable companies (NACE 477). It probably lies between €70,000 and €400,000. It is a rough estimate.
Is CURAPHARMA profitable?
In financial year 2025, CURAPHARMA made a profit of €7,040.
Where can I find the annual accounts of CURAPHARMA?
CURAPHARMA filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of CURAPHARMA due?
CURAPHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.